Drug Trial Radar · NCT06815965
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Oct 16, 2024
Primary completion
Mar 11, 2026
Study completion Mar 25, 2026
Sponsor
- Lead sponsor
- EIP Pharma IncIndustry
- Sponsor type
- Industry
- Collaborators
- CervoMed, Inc.
- First posted
- Feb 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to evaluate the safety and tolerability (side effects) and pharmacokinetics (drug levels in the body) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.
Conditions
- Dementia With Lewy Bodies (DLB)
Interventions
neflamapimodDrug
Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase 14 (p38α). It is administered orally in 40 mg capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability 80 mg neflamapimod given twice daily in patients with dementia with Lewy bodies.Time frame: From enrollment until the end of treatment at 24 weeks
- Evaluate the safety and tolerability of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.Time frame: From enrollment until the end of treatment at 24 weeks
- Evaluate the maximum plasma concentration (Cmax) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.Time frame: From enrollment until the end of treatment at 24 weeks
- Evaluate the trough plasma concentration (Ctrough) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.Time frame: From enrollment until the end of treatment at 24 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hôpital Lariboisière - APHP; Centre de Neurologie Cognitive
Paris, France
Strasbourg University Hospital (Les Hopitaux Universitaires de Strasbourg)
Strasbourg, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.